Critical Medicines Act

EMA Welcomes Political Agreement on Critical Medicines Act

EU legislators have reached a provisional political agreement on the proposed Critical Medicines Act, and the European Medicines Agency is positioning its shortages, innovation and monitoring tools to support implementation and strengthen the resilience of EU medicine supply chains. This signals forthcoming EU-level measures for pharmaceutical manufacturers and health systems focused on vulnerability assessments, industrial and procurement interventions, and coordinated action to prevent shortages of critical medicines.

13 May 2026, 12:39ema.europa.euEuropean Union

EU Council Circulates Four-Column Negotiation Table for Critical Medicines Regulation

EU legislators have entered an advanced negotiation phase on the Critical Medicines Act, circulating a detailed Council four‑column table that aligns Commission, Parliament and Council positions on a framework to secure the availability and supply of critical medicinal products and medicines of common interest. The emerging regime would hard‑wire strategic manufacturing projects, more resilient and Europe‑focused public procurement, coordinated stockpiling and joint purchasing into EU law, materially changing how pharmaceutical supply risks and dependencies are managed across the single market.

8 May 2026, 07:27data.consilium.europa.euEuropean Union

EDQM Webinar Explains New Reliance-Based and Fast-Track CEP Assessment Pathways (11 May 2026)

EDQM has introduced new reliance-based and fast-track assessment pathways for CEP applications, effective from March 2026, and is holding a free webinar on 11 May 2026 to explain eligibility, conditions, and timelines for applicants and CEP holders. These pathways can shorten CEP review where dossiers leverage prior approvals or address critical medicine shortages, so active substance manufacturers and MAHs should assess which of their products qualify and adjust regulatory and supply-continuity strategies accordingly.

22 Apr 2026, 21:03edqm.euEuropean Union

EU Radiopharmaceuticals Horizon-Scanning Report From EMA and HMA

In April 2026, EU medicines regulators published a horizon-scanning report on radiopharmaceuticals that highlights rapid innovation, regulatory gaps, and vulnerabilities in radionuclide supply and specialist capacity across the EU over the next decade. The analysis signals likely updates to EU guidance and GMP, closer alignment between medicines and radiation-protection rules, and new measures to secure radiopharmaceutical manufacturing and supply chains, so companies should anticipate tighter expectations and evolving market conditions rather than immediate new legal obligations.

21 Apr 2026, 15:04ema.europa.euEuropean Union

European Parliament Briefing On Public Health, Pharmaceutical Industry And Critical Medicines In Poland

European Parliament analysts have issued a March 2026 briefing for the SANT mission outlining Poland’s underfunded health system, growing pharmaceutical sector, and structural dependence on imported APIs and critical medicines. This signals sustained EU-level focus on medicines security and may foreshadow further policy pressure for local production, diversified sourcing, and more resilient procurement strategies affecting manufacturers active in Poland and across the EU.

16 Apr 2026, 10:38europarl.europa.euEuropean UnionPoland

EDQM Issues Guidance on Reliance-Based and Fast-Track Assessment of CEP Applications

EDQM has issued two new guidelines establishing reliance-based and fast-track pathways for the assessment of Certificate of Suitability applications, allowing certain CEP dossiers to be prioritised where conditions are met from March 2026. These pathways let applicants and regulators leverage prior approvals and critical-medicine shortage situations to accelerate CEP processing while maintaining full regulatory diligence, signalling quicker market access routes for key active substances used in medicines.

15 Apr 2026, 13:52edqm.euEuropean Union

Netherlands VWS Minister Confirms Structural Funding and Embedding of Pandemic Preparedness Programme

The Dutch government has committed €177 million annually to structurally embed pandemic preparedness into national health policy, focusing on surveillance, acute-care coordination, and medical countermeasure resilience. For life sciences and medical device sectors, this signals long-term investment in strategic stockpiling, supply chain resilience, and scalable production capacity for vaccines and diagnostics.

2 Apr 2026, 10:18zoek.officielebekendmakingen.nlNetherlands

European Commission Answer Outlines Availability Obligations for Gene Therapies and Links to Critical Medicines Act Proposal

The European Commission has confirmed that pharmaceutical reforms and the Critical Medicines Act will impose mandatory supply obligations and collaborative procurement for high-priority therapies. Companies risk losing market protection if products are not launched within three years, requiring a strategic overhaul of EU-wide distribution and market access plans.

31 Mar 2026, 19:21europarl.europa.euEuropean Union

European Parliament Debates Urban Wastewater Directive EPR Costs and Medicine Supply Risks

The European Parliament is debating the implementation of the Urban Wastewater Treatment Directive's EPR scheme, shifting micropollutant treatment costs to pharmaceutical and cosmetic producers. This creates significant long-term financial liabilities and supply chain risks, requiring firms to monitor national-level flexibilities that may mitigate costs for critical or low-margin products.

29 Mar 2026, 19:03europarl.europa.euEuropean Union

Norway Proposes Amendments to Pharmacy, Medicines and Medical Devices Laws to Implement EU Crisis Preparedness Regulations

Norway has proposed legislation to implement EU crisis preparedness rules, introducing mandatory supply chain reporting for medicines and medical devices. Impacted businesses must prepare for enhanced transparency obligations and the formal adoption of EUDAMED notification requirements to mitigate supply chain risks.

29 Mar 2026, 05:58regjeringen.noNorwayEuropean Economic Area

EU Council Circulates Final Compromise Text for New Medicinal Products and EMA Regulation

The EU Council has finalized the compromise text for the new Pharmaceutical Regulation, consolidating the authorization and supervision framework for human medicines. Companies must prepare for stricter supply chain transparency, mandatory shortage prevention plans, and a recalibrated system of market exclusivity incentives.

27 Mar 2026, 20:54data.consilium.europa.euEuropean Union

EU / France Commission Delivers Comments on Draft Decree on Medicinal Product Shortages (Notification 2025/0795/FR)

The European Commission has formally challenged France's draft decree on medicinal product shortages, signaling potential conflicts between national supply mandates and EU single market rules. Pharmaceutical operators should anticipate revisions to stockholding and distribution requirements as France adjusts the proposal to meet Commission concerns.

27 Mar 2026, 11:57ec.europa.euEuropean UnionFrance

Estonia Appoints First Essential-Service Pharmacies and Wholesalers for Medicine Supply

Estonia has designated the first pharmacies and wholesalers as essential service providers, mandating strict crisis-response and supply continuity obligations from February 2026. Impacted operators must align logistics and risk planning with new 48-hour restoration and 5-day autonomy standards to ensure pharmaceutical supply chain resilience.

26 Mar 2026, 11:44ravimiamet.eeEstonia

Estonian Agency of Medicines Announces 31 March Info Day for Marketing Authorisation Holders

The Estonian Agency of Medicines is convening a strategic briefing in March 2026 to address major EU pharmaceutical law reforms and supply chain resilience. Marketing authorization holders must prepare for evolving compliance standards regarding product availability, advertising, and technical variation procedures.

24 Mar 2026, 09:35ravimiamet.eeEstoniaEuropean Union

EU Member States Call for Environmental Permitting Omnibus to Accelerate Cross-Sector Permitting

Seven EU Member States are advocating for a consolidated environmental permitting omnibus to harmonize fragmented project-approval rules across the energy, industrial, and biotech sectors. This move toward regulatory simplification aims to reduce litigation risks and compliance costs for large-scale investments while maintaining national control over specific permitting timelines.

18 Mar 2026, 16:27data.consilium.europa.euEuropean UnionBelgiumCzechiaFranceIrelandLatviaSlovakiaLuxembourg

Bulgaria Proposes Temporary Export Ban On Certain Medicinal Products (TRIS 2026/0122/BG)

Bulgaria has notified a temporary export ban on critical medicinal products including insulins and SGLT-2 inhibitors scheduled for March to May 2026. Companies should anticipate localized supply chain restrictions as EU member states increasingly leverage emergency trade measures to mitigate domestic medicine shortages.

17 Mar 2026, 19:54technical-regulation-information-system.ec.europa.euEuropean UnionBulgaria

EU Environment Council: Member States Call For Cross-sector Environmental Permitting Omnibus

EU Member States are advocating for a consolidated environmental permitting omnibus to harmonize fragmented rules across major industrial and climate regulations. This initiative aims to reduce legal uncertainty and accelerate strategic projects by streamlining cross-sectoral permitting, signaling a shift toward more predictable industrial operational frameworks.

14 Mar 2026, 15:02data.consilium.europa.euEuropean Union

European Parliament Questions Commission on Urban Waste Water Treatment Directive and Medicine Supply Risks

European Parliament is challenging the Commission over concerns that new wastewater treatment fees for pharmaceutical and cosmetic producers could jeopardize medicine supply security. This political pressure suggests potential for implementation flexibility or mitigation measures as Member States roll out Extended Producer Responsibility schemes.

14 Mar 2026, 07:44eur-lex.europa.euEuropean Union

EU Parliament Public Health Committee Draft Agenda: Votes on EU Pharmaceutical Package and European Biotech Act (18–19 March 2026)

The European Parliament's SANT Committee will vote on the EU Pharmaceutical Package and review the European Biotech Act on March 18–19, 2026. This marks a decisive step toward a comprehensive regulatory overhaul of market authorization, supply chain resilience, and safety standards for the life sciences sector.

13 Mar 2026, 10:50europarl.europa.euEuropean Union

EU Parliament SANT Committee To Review Negotiations on Critical Medicinal Products Proposal

The European Parliament is advancing negotiations on a new framework to secure the supply and availability of critical medicinal products. This signals increasing legislative momentum toward mandatory supply chain resilience and shortage mitigation requirements for pharmaceutical operators.

13 Mar 2026, 08:37europarl.europa.euEuropean Union